ALung Technologies is an advanced medical device company for treating respiratory failure. The company is developing the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis, a less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patient’s lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
ALung’s Hemolung RAS was originally developed at the University of Pittsburgh. The device is limited by United States law to investigational use. ALung is conducting a pivotal investigational device exemption trial of the Hemolung Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary disease (COPD). The VENT-AVOID Trial is the first pivotal trial of extracorporeal carbon dioxide removal (ECCO2R) for treating patients with COPD exacerbations.
The company was founded in 1997 and is based in Pittsburgh, Pennsylvania.
Timeline
Funding rounds
People
Alex Cashman
Investor
Elizabeth Edwards
Investor
Evan Aloe
Investor
Lawrence Rosen
Investor
Lindsey Marra
Employee
Marc Brands
Investor
Marcia Rick Dawood
Investor
Paul Bieniek
Employee
